Polson (507645)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value per share of ₹10,252 provides tangible asset support, with P/B at only 1.40.
• Trailing earnings are positive, and the latest quarter remains profitable at ₹1 crore net profit.
• Small market cap of ₹177 crore leaves room for niche growth if specialty chemicals demand revives.
• ROCE of 6.16 percent is positive, showing some return on capital employed despite weak ROE.

Concerns

• Sales and profits are declining: sales down 2.08 percent and profits down 3.20 percent.
• ROE of 3.95 percent is far below what a quality compounder should generate.
• Piotroski F-Score of 3/9 suggests weak operational health and deteriorating fundamentals.
• Zero dividend yield means investors get no cash return while waiting for growth.

AI Analysis

Let me apply the same test I would to any business: what is the return on capital, and can it grow? Polson scores poorly on both. Return on equity is only 3.95 percent, and return on capital employed is 6.16 percent—barely above a fixed deposit, and nowhere near what I need for inflation protection. Sales are shrinking at 2.08 percent, profit at 3.20 percent, and the latest quarter still shows only ₹1 crore net profit on ₹22 crore sales. This is not a compounding machine. At ₹14,386, the market capitalisation is ₹177 crore. Paying 26.5 times trailing earnings for a declining business is the opposite of Graham's margin of safety. Book value per share of ₹10,252 gives some asset backing, but a P/B of 1.40 means you are paying a 40 percent premium for a business earning less than 4 percent on those assets. There is no dividend yield to compensate while you wait. The Piotroski F-Score of 3 out of 9 is a red flag; it suggests deteriorating fundamentals. I admire niche chemical companies, but I cannot admire this arithmetic. In India, specialty chemicals can have good moats, but I see no evidence of pricing power or growth here. If I owned it, I would ask why capital is trapped at such low returns. The 52-week range shows the stock near its high, but price momentum is not a substitute for earning power. This looks like a slow grower at best, and at worst a value trap. I need either a much lower price, or a clear operational turnaround improving ROE and reversing the declines, before I would consider it.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer